GHK-Cu

GHK-Cu is a copper(II)-binding human tripeptide (glycyl-L-histidyl-L-lysine) present endogenously in plasma, saliva and urine. The copper complex is the active species; the peptide acts as a carrier that delivers bioavailable copper to the enzymes and matrix processes that require it, without the toxicity of free circulating copper.

GHK was isolated from human plasma albumin in 1973 by Loren Pickart, identified as the factor responsible for aged hepatocytes adopting a more youthful phenotype when incubated in serum from younger donors. Plasma concentration declines with age, from roughly 200 ng/mL at 20 to roughly 80 ng/mL at 60 — a loss of more than half, tracking dermal thinning, loss of elasticity, slower wound closure, delayed recovery and follicular miniaturisation.

Regenerative activity was first characterised in hepatocyte renewal but generalises across tissue types: skin grafts, ligament and tendon, pulmonary connective tissue, osseous tissue, gastric and intestinal lining, and nerve. Documented effects run to the gene-expression level, including DNA repair activity and clearance of accumulated damaged proteins when proteostatic systems fail. It can substitute for corticosteroids in inflammatory dermatoses, and is generally positioned as the leading broad-spectrum anti-ageing peptide.

Regulatory status splits by route. Topical GHK-Cu, listed as Copper Tripeptide-1, is unrestricted in cosmetics with decades of use behind it. Injectable GHK-Cu is a research chemical, unapproved by the FDA for any injectable human use, and was placed on the FDA Category 2 bulk drug substances list in 2023, restricting 503A compounding on the basis of insufficient human safety data for parenteral routes.

Two routes are practical. Subcutaneous injection reaches systemic circulation and deep tissue — muscle, tendon, ligament, organs — that topical application never touches. Topical application of the reconstituted peptide in a cream or serum base covers localised dermatological indications and is the escape hatch for the substantial minority who cannot tolerate copper injections.

Copper delivery and enzyme activation. The copper moiety is an essential cofactor for lysyl oxidase, which cross-links collagen and elastin into mechanically competent networks; without adequate copper, newly synthesised collagen remains weak and degradation-prone. Copper is likewise required by antioxidant defence and energy-producing enzymes. GHK-Cu supplies it in a bound, tissue-targeted form rather than as free copper.

Gene expression modulation. Via the Broad Institute Connectivity Map, spanning over 7,000 gene expression profiles, GHK induces a 50% or greater change in expression in 31.2% of all human genes, shifting patterns towards healing and repair and away from inflammation, matrix breakdown and ageing. In an aggressive metastatic human colon cancer signature, GHK — out of 1,309 bioactive molecules studied — reversed expression of 70% of overexpressed genes, and increased expression of 47 DNA repair genes and 14 antioxidant genes. Effects are observed in the picomolar to nanomolar range.

Matrix synthesis. Fibroblast stimulation raises collagen Types I and III, elastin and glycosaminoglycans, plus decorin, a small proteoglycan governing collagen fibril organisation. Synthesis plus organisation underlies the firming, tendon and ligament, and scar-quality effects.

Metalloproteinase regulation. Rather than blanket inhibition, GHK-Cu promotes tissue inhibitors of metalloproteinases. In cell culture it increased MMP1 and MMP2 expression while increasing TIMP1 at all tested concentrations; the resulting rise in TIMP-to-MMP ratio was associated with increased collagen and elastin production, giving controlled removal of damaged matrix alongside new deposition.

Anti-inflammatory action. Reduced TNF-alpha, IL-6 and IL-1 beta, activation of cellular antioxidant systems, and preservation of reparative inflammation while suppressing chronic inflammation. Pickart et al. (2015) also describes activation of TGF-beta and integrin pathways and restoration of viability in irradiated fibroblasts.

Angiogenesis. VEGF release drives new vessel formation, mechanistically parallel to BPC-157, improving nutrient delivery and waste clearance at repair sites.

Cell migration and stem cell activation. Chemotactic recruitment of macrophages, mast cells and fibroblasts supports the full wound-healing cascade through remodelling; GHK-Cu also appears to mobilise dormant stem cells, with one study reporting a 160% increase in stem cell growth.

Dermal matrix. Stimulates collagen and elastin synthesis and improves hydration; restores elasticity and reverses age-related dermal thinning, described as more effective than most prescription retinols; reduces fine lines, wrinkles, photodamage and hyperpigmentation; provides UV protection. Badenhorst et al. (2016) recorded a 55.8% reduction in wrinkle volume and 32.8% reduction in wrinkle depth over 8 weeks of twice-daily topical use in 40 women aged 40 to 65; Abdulghani et al. (1998) found improved collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid.

Follicular. Accelerates hair growth equal to or better than minoxidil 5%; increases follicle size by up to 40% for greater shaft calibre; strengthens follicles. Tripeptide-copper complexes stimulate hair follicle elongation and dermal papilla cell proliferation in vitro at picomolar to nanomolar concentrations.

Regenerative. Accelerates wound healing by 30 to 50% in animal models, with one study showing 64.5% versus 28.2% reduction in wound area; improves contraction, granulation tissue formation, epithelialisation, collagen deposition and scar quality; reverses cortisone-induced inhibition of healing; stimulates angiogenesis and nerve fibre regeneration; reverses COPD-associated fibroblast phenotype. Systemic injection improves healing at distant sites.

Cytoprotective and genomic. Potent antioxidant and free-radical scavenger; potent anti-inflammatory capable of substituting for corticosteroids in inflammatory skin disease; DNA repair activity; clearance of accumulated damaged proteins under impaired proteostasis. Keratinocytes exposed to UV showed 70% viability with GHK-Cu versus 40% in controls.

Gastrointestinal. Mao et al. (2025), a DSS-induced colitis model in 32 BALB/c mice, showed reduced weight loss and disease activity index, restored ZO-1 and Occludin tight junction expression, suppressed TNF-alpha, IL-6 and IL-1 beta, and mucosal healing via the SIRT1/STAT3 pathway.

Oncological, neural and other. Multiple described anti-cancer mechanisms including prevention of metastasis in colon cancer; improved digestive health; increased neurotrophic factor production; preliminary evidence of partial reversal of age-related cognitive decline in mice; reduced anxiety and aggression; analgesia via decreased expression of pain genes.

Human data is confined largely to topical studies. Twice-daily facial application for 8 weeks produced a 55.8% reduction in wrinkle volume (p<0.001) and 32.8% reduction in wrinkle depth (p=0.012) in a randomised, double-blind trial; 12 weeks of daily use produced measurable gains in skin density, thickness and firmness with reduced fine lines and sagging. Follicular effects from topical application typically require 16 to 24 weeks. In the rat ACL reconstruction model (Fu et al., 2015), intra-articular GHK-Cu reduced knee laxity at 6 weeks, but the benefit did not persist at 12 weeks after treatment was discontinued.

Serum half-life is under one hour, which favours frequent low-dose administration over sporadic larger doses for stable tissue exposure.

User-reported timelines for injectable use, which are anecdotal rather than published:

Weeks 1 to 2. Improved skin texture and softness is near-universal; some report an early visible glow.

Weeks 4 to 6. Noticeable change in fine lines, skin thickness and complexion; some report resolution of minor injuries or reduced joint discomfort. One report describes crepey skin resolving with improved brightness and elasticity by the end of a 6-week run at 2 mg daily.

Weeks 8 to 12. More substantial shifts in skin quality — reduced wrinkle depth, improved firmness, fading of age spots. One long-term user described dry, sun-damaged skin becoming moist and soft after 6 weeks with continued improvement through 3 months on a GHK-Cu-containing blend.

Hair. Slower and less consistent. Some report faster growth without calibre change; others report nothing from injectable use alone. Topical application with microneedling appears to give more reliable follicular outcomes.

Non-response occurs: one report describes no skin or hair change after 3 mg daily for 2 months, a 1-month break, then 5 mg daily for a further 2 months. Healing reports are also confounded, since GHK-Cu is most often run inside blends with BPC-157 and TB-500.

Reconstitute a 50 mg vial with 2.5 to 3 mL bacteriostatic water; at 2.5 mL, 1 mg equals 5 units on an insulin syringe. A 100 mg vial takes 5 mL, giving 20 mg/mL. The solution turns blue or blue-green from the copper complex — expected, and its absence is the anomaly.

Standard subcutaneous protocol. 1 to 2 mg daily, daily or 5 days per week, 4 to 8 weeks with extension to 12 weeks, followed by a 4 to 6 week break. Conservative entry point: 0.5 to 1 mg daily, 3 to 5 times per week, to assess tolerance before escalation. No published dose-finding studies exist for subcutaneous protocols; these are practice patterns. Animal work used approximately 0.5 to 1.5 mg/kg by injection.

Serum half-life under one hour dictates frequent low-dose administration. Timing is flexible, night dosing preferred, fasted state not required — relevant when stacking with GH secretagogues, which do require fasting. Systemic distribution makes injection site largely irrelevant for general anti-ageing; for a localised target, injecting closer to the tissue raises local concentration before clearance.

Copper reactivity management, in order of effect: dilution — add 30 to 90 units of extra bacteriostatic water to the drawn dose; systematic site rotation with per-zone tracking, since thigh and abdominal response differ substantially between individuals; injection into fattier areas; antihistamine 30 minutes pre-injection; and co-administration with potent anti-inflammatory peptides, BPC-157 and KPV, as in the GLOW and KLOW blends, which reduces both pain and reaction incidence. Some report deeper intramuscular administration lessens the reaction.

Topical conversion. Cut the crimp, remove the stopper, add water gradually (approximately 0.5 mL / 50 units) while stirring the lyophilisate with the rubber end of a plunger until no dry powder remains, then transfer into a cream or serum base, mix thoroughly and refrigerate. Published topical work used 0.5% to 4% facial concentrations and 2% for the eye area, once or twice daily, continuously with no cycling. Compatible with hyaluronic acid, vitamin E, niacinamide, argireline, vitamin B, ceramides, collagen, elastin, Matrixyl 3000, leuphasyl, aloe vera, ferulic acid, squalane, glycerin, coenzyme Q10 and bakuchiol. Avoid retinoids, AHAs, BHAs, glycolic acid, salicylic acid and vitamin C as L-ascorbic acid.

Preclinical evidence is extensive and consistently positive; human data are confined almost entirely to topical dermatology, and no published human clinical data exist on injectable safety or efficacy.

Topical clinical. Badenhorst et al. (2016), Journal of Aging Science: randomised, double-blind, N=40 women aged 40 to 65, twice-daily GHK-Cu in lipid-based nanocarriers for 8 weeks — 55.8% reduction in wrinkle volume (p<0.001), 32.8% reduction in wrinkle depth (p=0.012) versus control serum, and 31.6% greater wrinkle volume reduction than Matrixyl 3000 (p=0.004); the in vitro arm confirmed increased collagen and elastin production and a favourable TIMP-to-MMP shift. Finkley et al. (2005), a book chapter rather than a peer-reviewed article: 12 weeks, 71 women with mild to advanced photoageing, significant gains in skin density and thickness, reduced fine lines and sagging, no adverse events. Abdulghani et al. (1998): improved collagen production in 70% treated versus 50% for vitamin C and 40% for retinoic acid; small study, minor journal.

Genomic. Pickart and Margolina (2018), Int J Mol Sci: Connectivity Map analysis across more than 7,000 expression profiles — GHK induces ≥50% expression change in 31.2% of all human genes at picomolar to nanomolar concentrations; of 1,309 bioactive molecules, GHK reversed expression of 70% of overexpressed genes in a colon cancer metastasis signature and raised 47 DNA repair and 14 antioxidant genes. Pickart et al. (2015), BioMed Research International: TGF-beta and integrin pathway activation, reduced TNF-alpha-induced IL-6 secretion, restored viability of irradiated fibroblasts. Both are reviews.

Regenerative. Maquart et al. (1993), J Clin Invest: concentration-dependent collagen synthesis in rat wound chambers, roughly twice the stimulation of non-collagen protein, with increased Type I and III collagen mRNA. Fu et al. (2015), J Orthop Res, N=48 rats, intra-articular administration in ACL reconstruction: reduced knee laxity at 6 weeks, benefit not sustained at 12 weeks after discontinuation.

Other preclinical. Mao et al. (2025), Front Pharmacol, N=32 BALB/c mice, DSS colitis: restored ZO-1 and Occludin, suppressed TNF-alpha, IL-6 and IL-1 beta, mucosal healing via SIRT1/STAT3. Kang et al. (2009): integrin alpha-6/beta-1 and p63 upregulation in keratinocytes. Pickart et al. (2012) and Dou et al. (2020) address oxidative stress and cognition. Pyo et al. (2007) used AHK-Cu, not GHK-Cu.